VIOLET临床试验方案:单中心I/II期试验评价[161Tb]Tb-PSMA-I&T放射性配体治疗转移性去势抵抗性前列腺癌患者
VIOLET是一项单中心、单臂I/II期试验,计划纳入30例转移性去势抵抗性前列腺癌(mCRPC)患者,评估[161Tb]Tb-PSMA-I&T的安全性、最大耐受剂量及抗肿瘤活性。剂量递增采用3+3设计,预设4.4、5.5和7.4 GBq三个活度水平,剂量扩展组在最大耐受剂量下纳入24例。主要目标是确定最大耐受剂量和安全性特征。
要点
- VIOLET试验评估[161Tb]Tb-PSMA-I&T在mCRPC患者中的安全性及最大耐受剂量。
- 剂量递增采用3+3设计,预设4.4、5.5、7.4 GBq三个活度水平。
- 最多6个周期,每6周静脉给药一次,后续活度每次减少0.4 GBq。
核心结论
- 研究旨在证明[161Tb]Tb-PSMA-I&T能向转移性前列腺癌病灶递送有效辐射且安全性可接受。
- 截至2024年2月已完成入组,患者仍在接受[161Tb]Tb-PSMA-I&T治疗。
研究设计与样本
- 单中心、单臂I/II期试验,计划招募30例mCRPC患者。
- 剂量递增采用3+3设计,预设4.4、5.5和7.4 GBq三个[161Tb]Tb-PSMA-I&T活度水平。
- 最大耐受剂量定义为在6例受试者中剂量限制性毒性发生少于2例的最高活度水平。
- 剂量扩展组在最大耐受剂量下纳入24例受试者。
主要发现
- [177Lu]Lu-PSMA是mCRPC的有效治疗类别,但疾病进展不可避免。
- 161Tb具有丰富的俄歇电子和转换电子发射,在较短路径内沉积更高浓度辐射,尤其对单个肿瘤细胞和微转移灶。
- 161Tb在体外和体内研究中显示出优于177Lu的疗效。
关键数值与推荐
- 关键入选标准包括:mCRPC诊断且至少一线紫杉烷化疗(除非医学上不适合)和雄激素受体通路抑制剂治疗后进展。
- [68Ga]Ga-PSMA-11或[18F]DCFPyL PET/CT显示前列腺特异性膜抗原阳性疾病(SUVmax ≥ 20)。
- [18F]FDG PET/CT未显示不一致病灶。
- 骨髓、肝脏和肾脏功能充足,东部肿瘤协作组体能状态评分不超过2,且未接受过其他放射性同位素治疗。
- 最多6个周期[161Tb]Tb-PSMA-I&T每6周静脉给药一次,后续每次活度减少0.4 GBq。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
[177Lu]Lu-PSMA is an effective class of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC); however, progression is inevitable. The limited durability of response may be partially explained by the presence of micrometastatic deposits, which are energy-sheltered and receive low absorbed radiation with 177Lu due to the approximately 0.7-mm mean pathlength. 161Tb has abundant emission of Auger and conversion electrons that deposit a higher concentration of radiation over a shorter path, particularly to single tumor cells and micrometastases. 161Tb has shown in vitro and in vivo efficacy superior to that of 177Lu. We aim to demonstrate that [161Tb]Tb-PSMA-I&T will deliver effective radiation to sites of metastatic prostate cancer with an acceptable safety profile. Methods: This single-center, single-arm, phase I/II trial will recruit 30 patients with mCRPC. Key eligibility criteria include a diagnosis of mCRPC with progression after at least one line of taxane chemotherapy (unless medically unsuitable) and androgen receptor pathway inhibitor; prostate-specific membrane antigen-positive disease on [68Ga]Ga-PSMA-11 or [18F]DCFPyL PET/CT (SUVmax ≥ 20); no sites of discordance on [18F]FDG PET/CT; adequate bone marrow, hepatic, and renal function; an Eastern Cooperative Oncology Group performance status of no more than 2, and no prior treatment with another radioisotope. The dose escalation is a 3 + 3 design to establish the safety of 3 prespecified activities of [161Tb]Tb-PSMA-I&T (4.4, 5.5, and 7.4 GBq). The maximum tolerated dose will be defined as the highest activity level at which a dose-limiting toxicity occurs in fewer than 2 of 6 participants. The dose expansion will include 24 participants at the maximum tolerated dose. Up to 6 cycles of [161Tb]Tb-PSMA-I&T will be administered intravenously every 6 wk, with each subsequent activity reduced by 0.4 GBq. The coprimary objectives are to establish the maximum tolerated dose and safety profile (Common Terminology Criteria for Adverse Events version 5.0) of [161Tb]Tb-PSMA-I&T. Secondary objectives include measuring absorbed radiation dose (Gy), evaluating antitumor activity (prostate-specific antigen 50% response rate, radiographic and prostate-specific antigen progression-free survival, overall survival, objective response rate), and evaluating pain (Brief Pain Inventory-Short Form) and health-related quality of life (Functional Assessment of Cancer Therapy-Prostate and Functional Assessment of Cancer Therapy-Radionuclide Therapy). Conclusion: Enrollment was completed in February 2024. Patients are still receiving [161Tb]Tb-PSMA-I&T.
引用
- Buteau JP, Kostos L, Alipour R, et al. Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T. J Nucl Med. 2024. PMID: 38991752. doi:10.2967/jnumed.124.267650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。